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A B S T R A C T
Purpose: The view that juvenile myoclonic epilepsy (JME) is a uniform and life-long disorder is currently
being challenged. The aim of this study was to assess the seizure and psychosocial outcome of JME at
least 20 years after onset.
Methods: In 1992, 42 patients with JME were identiﬁed. In 2012, 37 agreed to a semi-structured
interview. In the remaining ﬁve, only medical records were available.
Results: Of 40 patients with known seizure outcome, 21 were in remission for >5 years. Seven were off
antiepileptic drugs (AEDs), four being seizure free for >10 years. Myoclonic seizures (MC) evolving to
generalized tonic–clonic seizures (GTC) were associated with seizure persistence (p = 0.013), whereas
>1 year between MC and GTC onset was associated with a trend to GTC remission (p = 0.069). Of 19
patients with uncontrolled seizures, eight experienced remission with second generation AEDs.
Favorable psychosocial outcome by interview was found in a third, whereas another third had
psychiatric comorbidity, seven with substance or alcohol abuse. Psychosocial and seizure outcome did
not correlate.
Conclusion: This study corroborates the heterogeneity of JME in terms of seizure and psychosocial
outcome, but without a clear association between the two. It conﬁrms that seizure control may persist
after AED withdrawal in some and supports MC evolving to GTC as a predictor of seizure persistence.
Moreover, it suggests that newer broad spectrum AEDs may improve the prognosis of JME; their impact
should be focus of prospective studies.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) is the most common type of
genetic (idiopathic) generalized epilepsy, comprising 5–10% of all
epilepsies.1 Onset is usually in the second decade, and the cardinal
symptom is early-morning myoclonic seizures (MC), often
precipitated by sleep deprivation. Approximately 90% of patients
have generalized tonic–clonic seizures (GTC), and one third has
absence seizures.2
Although response to appropriate treatment is good for most
patients,3,4 JME has been considered a lifelong disorder with a high
risk of seizure relapse on discontinuation of antiepileptic drugs
(AEDs).5–7 Nevertheless, four long-term follow-up studies have* Corresponding author at: Department of Neurology and Clinical Neurophysiol-
ogy, St. Olav’s University Hospital, 7006 Trondheim, Norway. Tel.: +47 72575200;
fax: +47 72575775.
E-mail address: eylert.brodtkorb@ntnu.no (E. Brodtkorb).
1 These authors contributed equally and are joint second authors.
1059-1311/$ – see front matter  2014 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2014.01.012shown that some patients may stop AED treatment and remain
seizure free.8–11
In contrast to the seemingly positive seizure outcome in the
majority, there is expanding evidence of an unfavorable psycho-
social outcome in many patients.9,12 This has been ascribed to a
subtle frontal lobe dysfunction in JME.13,14
As long-term studies of JME are scarce, there is a need for more
clinical research on the course and prognosis of this syndrome.
Thus, we aimed to assess the severity of the disorder in a cohort of
patients after at least 20 years of follow-up, and to study clinical
characteristics in relation to seizure and psychosocial outcome.
2. Methods
In 1992, consecutive patients with JME at Trondheim University
Hospital were identiﬁed for recruitment in a study on the
association with human leukocyte antigens.15 The clinical
diagnosis of JME was based on the 1989 classiﬁcation of epilepsies
and epileptic syndromes by the International League Againstvier Ltd. All rights reserved.
Table 4
Unfavorable psychosocial factors in relation to seizure outcome in 37 patients with
JME after >20 years.
5-year seizure
remission
Seizures
within last
5 years
P-value
No high school graduation 4 (36%) 7 (64%) 0.087
Disability beneﬁts/unemployment 7 (50%) 7 (50%) 0.898
Substance abuse 3 (75%) 1 (25%) 0.316
Ever needed psychiatric health care 7 (54%) 6 (46%) 0.823
Poor self-reported social network 2 (40%) 3 (60%) 0.162
No unfavorable psychosocial factors 7 (50%) 7 (50%) 0.699
Table 1
Number of patients included in the various analyses after follow-up >20 years.
Original
cohort (1992)
Seizure
outcome
Psychosocial
outcome
Disability
beneﬁts
Interviewed 37 37 37 37
Unavailable 2 1 0 1
Deceased 3 2 0 2
Total 42 40 37 40
Table 2
Terminal seizure remission in 40 patients with JME after follow-up > 20 years.
Seizure remission Five years Ten years
Generalized tonic–clonic seizures 31 (78%) 24 (60%)
Myoclonic seizures 22 (55%) 16 (40%)
Both seizure types 21 (53%) 13 (33%)
Table 3
Clinical characteristics in relation to seizure outcome in 40 patients with JME
followed >20 years.
5-year
seizure
remission
Seizures
within last
5 years
P-value
Three seizure types 5 (50%) 5 (50%) 0.855
Absence seizures 5 (45%) 6 (55%) 0.583
Myoclonic seizures not
strictly conﬁned to awakening
6 (46%) 7 (54%) 0.564
Myoclonic seizures preceding GTC 8 (35%) 15 (65%) 0.013
>1 year between onset of
myoclonic seizures and GTC
9 (60%) 6 (40%) 0.464
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with a request for participation in a follow-up study.
One patient could not be included as he died after only 13 years
of follow-up. Two other deceased patients followed for more than
20 years were included based on their medical records. Two
patients could not be contacted as they were currently registered
with no ﬁxed address; in one medical records were sufﬁcient for
inclusion (Table 1).
37 patients (88%) were available for a standardized semi-
structured telephone interview, focusing on seizure types, seizure
frequency, medication and psychosocial outcome. Medical records
were reviewed for background information.
Psychosocial outcome was assessed based on ﬁve elements:
graduation from high school, disability or unemployment beneﬁts,
alcohol or illegal substance abuse causing social problems, need of
psychiatric health care and self-reported social network. Social
network, as well as perceived satisfaction with health, was simply
graded as poor, sufﬁcient or good, as more complex scales were
considered less useful for telephone interviews.
Chi-square test and independent t-test were used for compari-
son of categorical and continuous variables, respectively. p < 0.05
was considered signiﬁcant.
The study was approved by the Regional Committee for Medical
Research Ethics, and written informed consent was provided by all
interviewed participants.
3. Results
3.1. Patients
Of the 42 patients forming the basis of this study, 25 (60%) were
women. Forty patients (95%) had GTC and 12 (29%) had absences.
One patient had MC only. In ﬁve patients, GTC was the ﬁrst
reported seizure type. The duration of JME, calculated from onset
of the ﬁrst motor seizure (MC or GTC) was 31  9.3 years. Mean age
at JME onset was 16  3.2 years (women 15  3.1, men 17  3.0,
p = 0.056). In three female patients, absences were the ﬁrst seizure
type, with onset at age eight, nine and 12 years, respectively,
whereas MC started at age 18 in the two ﬁrst, and at age 19 in the
third.
In the three deceased patients, causes of death were suicide
(age 28), cancer (age 59) and dementia (age 81).
3.2. Seizure outcome
In 40 patients seizure outcome was known at least 20 years
after JME onset. Median age at follow up was 47 (range 35–81)
years.
The ﬁve and ten-year seizure remission rates for GTC and MC
are shown in Table 2. More than 50% had been completely seizure-
free for the last ﬁve years, and one-third for at least ten years.
Altogether 19 patients had persistent seizures within the last ﬁve
years; one had GTC only, ten had MC only and eight had both
seizure types. Of the 18 interviewed patients with persistent MC,
all but two (age 39 and 41) reported a reduced frequency compared
to younger years.None of the three patients with absence epilepsy prior to MC
onset had experienced seizure remission. All were females. Two
had persistent MC and GTC; one had been without GTC for more
than ten years, but still had occasional MC without taking AEDs.
The relationship between various clinical characteristics and
ﬁve-year seizure remission is shown in Table 3. MC habitually or
occasionally preceding GTC (clonic–tonic–clonic seizure) was
associated with a poorer seizure outcome. Fifteen patients had a
delay of more than one year between MC onset and ﬁrst GTC. At
follow-up, 11 of them had not had GTC for more than ten years
(p = 0.069). However, the longer interval between MC and GTC
onsets, did not inﬂuence ﬁve year complete seizure remission
(Table 3). There was no difference in age at JME onset between
patients with ﬁve-year seizure remission and patients with
ongoing seizures (16  3.9 years vs. 16  2.3 years, p = 0.494).
Eleven women (44%) and ten men (67%) had been seizure-free for
more than ﬁve years (p = 0.165). Seizure persistence was not
associated with poor satisfaction with health (p = 0.506).
3.3. Psychosocial outcome
Fourteen of the 37 interviewed patients (38%) had a favorable
psychosocial outcome, meaning they had graduated from high
school, were working, had no history of a psychiatric disorder, had
a good or sufﬁcient social network and no substance or alcohol
abuse. Altogether 26 (70%) had graduated from high school, and 12
(32%) were college or university graduates, one with a PhD degree.
There was no association between these factors and seizure
outcome (Table 4).
We were able to obtain information on employment and
disability beneﬁts from 40 patients. Twenty-three patients (58%)
Table 5
The use of second generation antiepileptic drugs in 40 patients with JME followed
>20 years.
AED Ever used Current use Retention
rate (%)a
Levetiracetam 17 10 59
Lamotrigine 16 8 50
Topiramate 11 6 55
a The rate of patients with continued use of the drug for >1 year at follow-up.
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unemployed. Fourteen (35%) received disability beneﬁts, but only
half of them due to epilepsy alone; other causes included
psychiatric disorders, chronic pain, multiple sclerosis and rheu-
matoid arthritis.
Thirteen of the interviewed patients (35%) had received
psychiatric care, nine (24%) for depression, four for anxiety and
two for psychosis. Four admitted alcohol or illegal substance abuse.
According to medical records, one of the patients with no ﬁxed
address and two of the deceased also had such problems. Four of
these patients had been convicted prisoners.
At interview, 32 patients (86%) reported their social network to
be good (18 patients) or sufﬁcient (14 patients). As many as 28
(76%) were satisﬁed (23 patients) or very satisﬁed (ﬁve patients)
with their health, including three of the seven receiving disability
beneﬁts mainly for comorbid conditions. Of the nine patients who
were unsatisﬁed, four had a good seizure outcome. Even in the 18
interviewed patients with occurrence of seizures during the last
ﬁve years, the majority were satisﬁed (ten patients) or very
satisﬁed (three patients) with their health.
There was no association between psychosocial outcome and
gender, age at onset or duration of epilepsy prior to initiation of
treatment (data not shown).
3.4. Treatment and follow-up
Seven patients (18%) had stopped AED treatment. Four of them
had been completely seizure-free for more than ten years after
withdrawal. Two still had occasional MC, but no GTC. One had a GTC
within the last year, but reported several years between seizures.
Four of the seven patients who had discontinued medication, did so
on their own initiative, two without medical supervision.
Of those remaining on treatment, 17 patients used mono-
therapy, and 18 a combination of AEDs. Among the 17 patients
with ﬁve-year seizure remission still using AEDs, 10 had
monotherapy, mainly valproate (seven).
Valproate had been used by all, apart from three females. The
second generation broad-spectrum AEDs, lamotrigine, levetirace-
tam and topiramate had been tried in a total of 21. The retention
rates, denoting continued use >1 year at follow-up, are shown in
Table 5. Of the 19 patients who had received second generation
AEDs for uncontrolled seizures for more than ﬁve years, eight
obtained seizure remission, four of them after the introduction
of levetiracetam. The remaining patients used lamotrigine inTable 6
Comparison of long-term follow-up studies of JME.
Design Patient
number
Lost to
follow-up
Baykan et al. (2008) Hospital-based 48 Not reported 
Camﬁeld and Camﬁeld (2009) Population-based 23 4% 
Geithner et al. (2012) Hospital-based 31 56% 
Senf et al. (2013) Hospital-based 66 19% 
Present study Hospital-based 40 5% 
a At any time during follow-up; the other ﬁgures denote terminal remission.combination treatment. However, lamotrigine was withdrawn in
ﬁve other patients due to more frequent MC. Levetiracetam, in
contrast, was speciﬁcally reported to reduce MC in four, but
treatment was stopped in another ﬁve due to an apparent GTC
increase. Topiramate was considered beneﬁcial in the six patients
remaining on treatment, partly by counteracting valproate-induced
weight gain.
Thirteen patients (33%) had not seen a neurologist for more
than ten years. Only seven of them had been seizure-free for more
than ﬁve years. Two had a GTC less than one year earlier. One had
several unfavorable social factors, including substance abuse.
Beyond that, we found no association between drop-out from
follow-up and social outcome.
4. Discussion
4.1. Seizure outcome
This study contributes to the knowledge on the long-term seizure
prognosis of JME by investigating 40 patients after a mean of 31 years
after onset. After at least 20 years, more than half of the patients had
been seizure-free for at least ﬁve years. Seven had stopped using
AEDs, and four had remained seizure-free off medication for as long
as ten years, suggesting epilepsy as no longer present.
To our knowledge, four other studies have followed JME cohorts
for decades, all of them published since 20088–11 (Table 6). Due to
different methodology, these studies are only partly comparable. A
limited number of patients were included in each study, and
different aspects of the disorder were addressed.
The most extensive long-term study, with regard to both patient
number and follow-up time, is from Berlin, reporting on patients
originally selected by Dieter Janz, the ﬁrst to describe JME as a
speciﬁc syndrome. Five-year seizure remission was just below 60%,
and nearly one ﬁfth remained seizure-free off medication.11This is in
accordance with another recent study from Germany.10However, in
the latter study, more than half of the screened patients were lost to
follow-up, presumably leaving out a number of patients with poor
prognosis. A strength of our study is the very low drop-out rate.
Baykan et al. reported 48 patients from Turkey attending
regular visits to an epilepsy center for an average of 20 years.
According to their ﬁndings, MC subside in the fourth decade of life.
More than 50% no longer had MC at follow-up.8 Our ﬁndings were
similar; all but two of our patients had experienced a considerable
improvement of MC, and more than half were in complete
remission. MC may sometimes be under-reported, as not all
patients interpret single jerks as seizures. Like Baykan et al., we
speciﬁcally asked for MC after describing such seizures carefully.
Five-year seizure remission in the Turkish study was low (27%).
An inclusion criterion was at least seven years of follow-up at the
epilepsy clinic prior to inclusion. Thus, the selection of participants
appeared to be biased toward patients with more severe epilepsy
actively seeking medical advice and follow-up. Our study is also
hospital-based and may accordingly be biased toward difﬁcult-to-
treat epilepsy as well, but it also includes patients dropping out ofMean
follow-up
(years)
Mean age
at onset
5-year
seizure
remission
Patients off
medication
5-year seizure
remission off
medication
20 14 13 (27%)a 9 (19%) 4 (8%)
26 10 7 (30%) 11 (48%) 6 (26%)
39 13 21 (68%) 6 (19%) 6 (19%)
45 14 39 (59%) 12 (18%) 11 (17%)
31 16 21 (53%) 7 (18%) 4 (10%)
M.R. Syvertsen et al. / Seizure 23 (2014) 344–348 347regular specialist care. Conceivably, more patients with seizure
control are covered, as well as those with poor psychosocial
outcome. Nevertheless, common ﬁndings in these long-term
hospital-based studies are the lower seizure remission rates
compared to studies on new onset or valproate-naı¨ve patients
(80%).4,17 It is noteworthy that studies with the longest follow-ups
show the best seizure outcomes (Table 6), a ﬁnding which may
reﬂect a general improvement with age.
The only population-based study9 differed from the other
studies in several respects, including eager attempts to discontinue
treatment and inclusion of only patients with pediatric seizure
onset age (mean ten years). As many as 18 of the 23 patients tried
AED withdrawal after initial successful treatment. Eleven
remained off medication, but only six stayed completely seizure
free; ﬁve were left with rare or non-intrusive seizures. Only one
patient among those who never tried to stop treatment achieved
terminal remission exceeding 5 years (Table 6).
Moreover, patients with prior absence epilepsy progressing to
JME were excluded from that study, as this subgroup may have a
different outcome. Female preponderance and poor treatment
response have been pointed out as characteristics of childhood
absence epilepsy progressing to JME.7 In our study, all three patients
with absence epilepsy evolving to JME were females with persistent
seizures, contributing to a gender skewed seizure outcome. In the
Berlin study, additional absence seizures with onset at 12 years or
later were also a negative predictor of seizure outcome.11 Differing
results in various studies may partly be due to the limited number of
patients in each of them; in addition, the subtle manifestations of
absences may sometimes have been neglected.
The majority of patients not taking AEDs in the present study
had discontinued treatment on their own initiative. Others report
similar ﬁndings.10 Results from the ﬁve long-term studies of JME
published to date, including our own, suggest that the current
common practice of keeping all patients on life-long AED
treatment should be less strict (Table 6).
We found a trend to an association between GTC remission and a
longer interval between onset of MC and the ﬁrst GTC. It is not
surprising that a delay of the occurrence of GTC denotes a lower
tendency to later GTC. If supported by further studies, it might
nevertheless serve as a useful predictor of a subsequent remission of
the most intrusive seizure type. Like Geithner et al., we found that
MC evolving to GTC predicted an unfavorable seizure outcome.10
No previous studies have addressed the effect of the new
generation of broad spectrum AEDs on the long term outcome of
JME. An appropriate assessment of sustained drug efﬁcacy was not
possible in this study, partly as background medications were
often changed, and probably also due to the development of the
disorder itself and the lessened impact of seizure-provoking
factors with age. Nevertheless, half of the patients in the present
study had tried second generation AEDs for uncontrolled seizures,
and 40% of them subsequently achieved at least ﬁve-year seizure
remission. The highest retention rate at ﬁnal follow up was found
for levetiracetam (Table 5), which is suggested to have a speciﬁc
antimyoclonic effect.3 After introduction of levetiracetam, seizure
freedom was obtained in 20–30% of patients, similar to ﬁndings in
a previous prospective study.18 However, this drug should be used
with care, as some patients experience an increased tendency to
GTC. Remarkably, levetiracetam and lamotrigine may have an
opposite effect on MC.3
4.2. Psychosocial outcome
Several studies have conﬁrmed that many people with JME
have a peculiar personality proﬁle and a trend toward social
maladjustment,14,19,20 but few long-term studies have focused on
the relation of seizure and psychosocial outcome. One third of thepresent patients had at some time received psychiatric health care,
but no correlation with long-term seizure outcome was found
(Table 4). Previous studies have reported an increased risk of
psychiatric comorbidity in JME.19,21 A French group identiﬁed a
clear association between the presence of psychiatric disorders
and AED-resistant seizures in newly diagnosed patients22, a
ﬁnding which may have been related to ongoing psychiatric
problems and an early stage of the disorder. This ﬁnding has been
supported by other studies.21 The different results in our study
may be due to the natural course of JME and its treatment.
Moreover, the current development of social welfare facilitating
social and vocational integration in our part of the world may have
contributed to a reduced interaction between seizures and a
history of psychiatric disorders.
Social problems, impulsivity, sleep/wake rhythm, decision-
making and risk-taking behavior in JME have been highlighted by
several authors.12,14 Dieter Janz, in his early reports, considered
these patients to have ‘‘. . .an engaging, but emotionally unstable,
fairly immature personality. . ..’’5 Some patients with JME have a
tendency to non-compliance concerning both drug adherence and
seizure provoking factors, as well as to missing out on outpatient
appointments.8,20 Nevertheless, some aspects of these character-
istics may be perceived as attractive.23 Conceivably, this personal-
ity proﬁle might explain why most patients with uncontrolled
seizures reported satisfaction with health.
A predominance of these typical personality traits in patients
with ongoing seizures within the last year has recently been
shown,14 but was not reﬂected as an association between seizure
and psychosocial outcome in the present study (Table 4). These
features have received ample attention in recent literature. The
main focus of interest has been a JME-associated frontal lobe
impairment, demonstrated both on neuropsychological tests and
by sophisticated imaging techniques.13 Moreover, the juvenile
onset of the disorder affects people in a vulnerable phase of life
concerning education, identity-formation and socializing. In
accordance with ﬁndings in older patients with JME,24 it is our
clinical impression that these problems prevail in the early stage of
the disorder. The development of the personality proﬁle with age
should be the focus of future prospective long-term studies.
Camﬁeld and Camﬁeld also emphasized that several of their
patients had an unfavorable psychosocial outcome, including
depression and unemployment.9 A history of substance or alcohol
abuse was present in many patients (17%) in our original cohort,
and in some even a criminal record (10%). One of these patients had
died from suicide. The use of illegal drugs and alcohol in patients
with JME should receive attention, both clinically and in future
research. Moreover, specialist follow-up should not exclusively be
left to the patients’ own initiative, as they may exhibit a striking
indifference to the consequences of the disorder. Seven of our
patients had not seen a neurologist for more than ten years, in spite
of ongoing seizures.
The lack of a comparable non-JME control group and a
standardized questionnaire for collection of psychosocial data
are clear limitations of this study. The fact that few subjects of the
original cohort were lost to follow-up is a strength; however, small
hospital-based studies cannot truly reﬂect all aspects of the
average JME population.
Nevertheless, this study demonstrates that a substantial
number of people with JME seem to manage well. Negative
psychosocial elements were absent in more than one third of our
patients. Many were ﬁnancially independent with a satisfactory
educational achievement; one was even a PhD graduate. In
addition to the great diversity of social ability, and the well-known
differences in response to treatment, neuropsychological testing
has also demonstrated variable and slightly contradictory
results.13 The heterogeneity of JME is also corroborated by genetic
M.R. Syvertsen et al. / Seizure 23 (2014) 344–348348ﬁndings; ﬁve different Mendelian genes and several susceptibility
loci have currently been identiﬁed.25
5. Conclusion
The clinical diversity of JME is remarkable, but so far we are left
with few signiﬁcant early prognostic predictors. The present study
conﬁrms that MC evolving to GTC is associated with a poor seizure
outcome. It suggests that a long period with only MC prior to the
ﬁrst GTC, may indicate a future remission of GTC. The new broad
spectrum AEDs appear to have the potential to reduce the
proportion of pharmacoresistant patients; levetiracetam is partic-
ularly promising. Moreover, current ﬁndings support a more
relaxed attitude to the recommended life-long treatment of JME, as
a number of patients remain in remission after AED withdrawal.
Many people with JME are burdened by psychosocial maladjust-
ment, including psychiatric comorbidity, in some cases even
substance and alcohol abuse, as well as criminal behavior. Efforts
to counteract this dangerous development in young people at risk
should be part of an active and supportive comprehensive epilepsy
service.
Notwithstanding, we wish to emphasize that a large number of
patients in this study had a favorable psychosocial outcome, often
independent of seizure outcome. A stigma of negative expectations
should not be transferred to these patients, as they appear to belong
to a variant of JME devoid of a manifest adverse personality proﬁle.
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